Adjunction of inhaled amikacin to intravenous standard-of-care antibiotics do not modified short term prognosis of Ventilator Associated Pneumonia due to Gram-negative bacilli. ( Niederman MS. et al. )

Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.

| Dr Olivier Leroy

The ESCMID recommendations published in 2017 (ATB-VAC 31/5/2017) are clear: the use of inhaled antibiotics in ICU should be prohibited. … Suite  

In patients with septic shock, it is likely that meropenem should be used with a loading dose and higher doses than recommended. ( Kothekar AT, et al. )

Clinical pharmacokinetics of 3 h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram negative bacteria

| Dr Olivier Leroy

Meropenem break points for enterobacteriacea, P. aeruginosa and A. baumannii, range from 2 to 8 mg/l.  The usual recommended doses … Suite  

In units with high rates of resistance empirical use of colistin in the treatment of late ventilator-associated pneumonia cannot be recommended. ( Cisneros JM. et al. )

Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.

| Dr Olivier Leroy

Multidrug-resistant gram-negative bacilli (MDR-GNB), including Pseudomonas aeruginosa, Acinetobacter baumannii, and extended-spectrum beta-lactamase (ESBL)-producing or carbapenemase-producing Enterobacteriaceae, are currently the pathogens … Suite